WHO ICTRP trial
A randomized, double-blind, placebo-controlled clinical study of Lianhua Qingwen…
ChiCTR2200058079 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2200058079 |
|---|---|
| Public title | A randomized, double-blind, placebo-controlled clinical study of Lianhua Qingwen capsule in the treatment of asymptomatic patients with novel coronavirus pneumonia |
| Scientific title | A randomized, double-blind, placebo-controlled clinical study of Lianhua Qingwen capsule in the treatment of asymptomatic patients with novel coronavirus pneumonia |
| Primary sponsor | Ruijin Hospital, Shanghai Jiaotong University School of Medicine |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Countries | China |
| Conditions | Novel Coronavirus Pneumonia (COVID-19) |
| Interventions | Experimental group:Lianhua Qingwen capsule;Control group:Placebo |
| Registration date | Mar 29, 2022 |
| Target size | Experimental group:800;Control group:800 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: